Smartlab Europe

Drug Research

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million. The Series E funding was supported by existing investors including dievini Hopp Biotech holding,...

VarmX Announces Publication in Nature Communications of Groundbreaking Snake Venom Inspired Approach to Restore Blood Clotting in Patients Using Anticoagulants

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, announced the publication in Nature Communications of a ground breaking LUMC study(1) on modified human factor X as a...

NeuroRx awarded FDA Fast Track Designation for first drug regimen targeting suicide in bipolar depression

NeuroRX , Acute Suicidal Ideation and Behavior (ASIB) , NRX-100 (ketamine HCl) , NRX-100 (ketamine HCl) , NeuroRx, a clinical stage biopharmacompany developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track...

AstraZeneca and Takeda establish collaboration to develop MEDI1341 for Parkinson’s disease

AstraZeneca and Takeda Pharmaceutical Company Limited announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD). Alpha-synuclein (α-synuclein) is...

Driving Patient Engagement in Alzheimer’s Disease Clinical Research to Achieve Trial Success

Worldwide, around 47 million people have dementia, and there are 9.9 million new cases every year, according to recent data from the World Health Organization (WHO)1.Alzheimer's disease (AD) is the most common cause of dementia and may contribute to...

licensure announnced by wuxi biologics and gloria pharmaceuticals of the fully human pd-1 antibody, gls-010 , to arcus biosciences

WuXi Biologics a global leadingopen-access biologics technology platform company offering end-to-end solutions for biologicsdiscovery, development and manufacturing, and its Chinese partner Harbin Gloria PharmaceuticalsCo Ltd , today announced that an exclusive license to the anti-PD-1 antibody...

InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US

InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients. “We are pleased that the FDA has granted orphan-drug designation for...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »